Pharmacokinetic study of liposome-encapsulated and plain mepivacaine formulations injected intra-orally in volunteers
- 16 December 2011
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Pharmacy and Pharmacology
- Vol. 64 (3) , 397-403
Abstract
Objectives The pharmacokinetics of commercial and liposome‐encapsulated mepivacaine (MVC) injected intra‐orally in healthy volunteers was studied. Methods In this double blind, randomized cross‐over study, 15 volunteers received, at four different sessions, 1.8 ml of the following formulations: 2% MVC with 1 : 100 000 epinephrine (MVC2%EPI), 3% MVC (MVC3%), 2% and 3% liposome‐encapsulated MVC (MVC2%LUV and MVC3%LUV). Blood samples were collected pre dose (0 min) and at 15, 30, 45, 60, 90, 120, 180, 240, 300, 360 min after injections. Liquid chromatography‐tandem mass spectrometry was used to quantify plasma MVC concentrations. Results Pharmacokinetic analysis showed that the maximum plasma concentration (Cmax) and the areas under the curves (AUC0–360 and AUC0–∞) after MVC2%LUV and MVC2%EPI injections were smaller (P < 0.05) than the equivalent figures for MVC3% and MVC3%LUV. The time to maximum plasma concentration (Tmax) and the half‐life of elimination (t½beta) obtained after the treatment with MVC2%LUV, MVC2%EPI, MVC3% and MVC3%LUV presented no statistically significant differences (P > 0.05). Cmax, AUC0–360 and AUC0‐∞ after injection of the 2% formulations (MVC2%LUV and MVC2%EPI) did not exhibit statistically significant differences (P > 0.05). The pharmacokinetics of MVC2%LUV were comparable to the pharmacokinetics of MVC2%EPI. Conclusion The liposomal formulation of 2% MVC exhibits similar systemic absorption to the local anesthetic with vasoconstrictor.Keywords
This publication has 24 references indexed in Scilit:
- Drug Delivery Systems for Local AnestheticsRecent Advances in Drug Delivery and Formulation, 2010
- Liposomal Drug Delivery Systems: An Update ReviewCurrent Drug Delivery, 2007
- Recent advances with liposomes as pharmaceutical carriersNature Reviews Drug Discovery, 2005
- Encapsulation of mepivacaine prolongs the analgesia provided by sciatic nerve blockade in miceCanadian Journal of Anesthesia/Journal canadien d'anesthésie, 2004
- Kinetic and dynamic studies of liposomal bupivacaine and bupivacaine solution after subcutaneous injection in ratsJournal of Pharmacy and Pharmacology, 2002
- DRV Liposomal Bupivacaine: Preparation, Characterization, and In Vivo Evaluation in MicePharmaceutical Research, 2001
- Comparison of Skin Anesthetic Effect of Liposomal Lidocaine, Nonliposomal Lidocaine, and EMLA Using 30-minute Application TimeDermatologic Surgery, 1998
- Neurotoxicological Assessment After Intracisternal Injection of Liposomal Bupivacaine in RabbitsAnesthesia & Analgesia, 1997
- Plasma concentrations of bupivacaine after brachial plexus administration of liposome-associated and plain solutions to rabbitsCanadian Journal of Anesthesia/Journal canadien d'anesthésie, 1993
- Prolongation of Canine Epidural Anesthesia by Liposome Encapsulation of LidocaineAnesthesia & Analgesia, 1992